- Adding atezolizumab to standard bevacizumab plus carboplatin plus paclitaxel (ABCP) offered better OS and PFS in patients with chemotherapy-naive NSCLC and sensitizing epidermal growth factor receptor (EGFR) mutations or baseline liver metastases.
Why this matters
- This therapy might be an option for these patient subgroups, especially those with sensitizing EGFR mutations who have progressed on tyrosine kinase inhibitor therapy.
- Randomized, open-label, international, phase 3 IMpower150 trial.
- 1202 patients with chemotherapy-naive metastatic NSCLC received ABCP (n=400), ACP (n=402), or BCP (n=400).
- Funding: F. Hoffmann-La Roche, Genentech.
- ABCP yielded better OS than BCP in:
- Patients with sensitizing EGFR mutations (HR, 0.31; 95% CI, 0.11-0.83);
- Patients with baseline liver metastases (HR, 0.52; 95% CI, 0.33-0.82).
- ABCP yielded better PFS than BCP in:
- Patients with sensitizing EGFR mutations (HR, 0.41; 95% CI, 0.23-0.75);
- Patients with baseline liver metastases (HR, 0.41; 95% CI, 0.26-0.62).
- No improvement in OS with ACP compared with BCP.
- Grade 3-5 adverse events were slightly higher in ABCP group compared with the other groups.
- Small subgroup sample sizes.